Diagnosis and treatment of prolactinomas

References

• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary8(1), 3–6 (2005).
   PubMedGoogle Scholar
• Herman V. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab.71(6), 1427–1433 (1990).
   PubMed Web of Science ®Google Scholar
• Karga HJ, Alexander JM, Hedley-Whyte ET et al. Ras mutations in human pituitary tumors. J. Clin. Endocrinol. Metab.74, 914–919 (1992).
   PubMed Web of Science ®Google Scholar
• Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J. Biol. Chem.275, 7459–7461 (2000).
   PubMedGoogle Scholar
• Yu R, Lu W, Chen J et al. Overexpressed pituitary tumor-transforming gene causes aneuploidity in live human cells. Endocrinology144, 4991–4998 (2003).
   PubMedGoogle Scholar
• Finelli P, Pierantoni GM, Giardino D. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res.62, 2398–2405 (2002).
   PubMed Web of Science ®Google Scholar
• Ezzat S, Zheng L, Zhu XF et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest.109, 69–78 (2002).
   PubMed Web of Science ®Google Scholar
• Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol. Endocrinol.18, 2543–2552 (2004).
   PubMed Web of Science ®Google Scholar
• Facchetti M, Uberti D, Memo M et al. Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. Mol. Endocrinol.18, 162–172 (2004).
   Google Scholar
• Pannett AA, Thakker RV. Multiple endocrine neoplasia type 1. Endocr. Relat. Cancer16, 449–473 (1999).
   Google Scholar
• Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry65, 1607–1618 (2004).
   PubMed Web of Science ®Google Scholar
• David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperodine, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther.22, 1085–1096 (2000).
   PubMed Web of Science ®Google Scholar
• Damsa C, Bumb A, Bianchi-Demicheli F et al. Dopamine-dependent side effects of selective serotonin reuptake inhibitors: a clinical review. J. Clin. Psychiatry65(8), 1064–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc.80(8), 1050–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Pollock A, McLaren EH. Serum prolactin concentrations in patients taking neuroleptic drugs. Clin. Endocrinol.49(4), 513–516 (1998).
   Google Scholar
• Sluijmer AV, Lappohn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil. Steril.58, 72–77 (1992).
   Google Scholar
• Petakov MS, Damjanovic SS, Nikolic-Durovic MM et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J. Endocrinol. Invest.21(3), 184–188 (1998).
   Google Scholar
• Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J. Clin. Endocrinol. Metab.90, 3927–3932 (2005).
   PubMed Web of Science ®Google Scholar
• Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J. Endocrinol. Invest.18(6), 436–441 (1995).
   PubMed Web of Science ®Google Scholar
• Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab.60(4), 698–705 (1985).
   PubMed Web of Science ®Google Scholar
• Liuzzi A, Dallabonzana D, Oppizzi G et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med.313(11), 656–659 (1985).
   PubMed Web of Science ®Google Scholar
• Verhelst J, Abs R, Maiter, D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab.84, 2518–2522 (1999).
   PubMed Web of Science ®Google Scholar
• Di Sarno A, Landi ML, Cappabianca, P et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J. Clin. Endocrinol. Metab.86(11), 5256–5261 (2001).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Sarnacchiaro F et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab.82(3), 876–883 (1997).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Dopamine resistance of prolactinomas. Pituitary6(1), 19–27 (2003).
   Google Scholar
• Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinemia and inhibition lactation. Drug Safety14(4), 228–238 (1996).
   PubMed Web of Science ®Google Scholar
• Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition lactation. Drug49, 255–279 (1995).
   PubMed Web of Science ®Google Scholar
• Ono M, Miki N, Kawamata T et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab.93(12), 4721–4727 (2008)
   PubMed Web of Science ®Google Scholar
• Kars M, Delgado V, Holman ER et al. Aortic valce calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab.93(9), 3348–3356 (2008).
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Livadariu E, Markov M et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol.159(1), 1–5 (2008).
   PubMed Web of Science ®Google Scholar
• Wakil A, Rigby AS, Clark AL et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur. J. Endocrinol.159(4), R11–R14 (2008).
   Web of Science ®Google Scholar
• Bogazzi F, Buralli S, Manetti L et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int. J. Clin. Pract.62(12), 1864–1869 (2008).
   PubMed Web of Science ®Google Scholar
• Colao A, Galderisi M, DiSarno A et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab.93, 3777–3784 (2008)
   PubMed Web of Science ®Google Scholar
• Devlin JK, Lakhani VT, Byrd BF et al. The prevalence of valvular heart disease in a cohort of patients taking cabergoline for the management of hyperprolactinemia. Presented at: Program of the 90th Annual Meeting of the Endocrine Society, San Francisco, CA, USA, 12–15 June 2008 (Abstract P3-748).
   Google Scholar
• Herring N, Szmigielski C, Becher H et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol.70(1), 104–108 (2009).
   PubMed Web of Science ®Google Scholar
• Nachtigall LB, Valassi E, McCaty D et al. Cardiac valvular function in hyperprolactinemic patients receiving cabergoline. Presented at: Program of the 90th Annual Meeting of the Endocrine Society, San Francisco, CA, USA, 12–15 June 2008 (Abstract 0R27-2).
   Google Scholar
• Vallette S, Serri K, Rivera J. et al. Long term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary DOI: 10.1007/s11102-008-0134-2 (2008) (Epub ahead of print).
   Google Scholar
• Molitch M. The cabergoline-resistant prolactinoma patient: new challenges. J. Clin. Endocrinol. Metab.93(12), 4643–4645 (2008).
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N. Engl. J. Med.331(14), 904–909 (1994).
   PubMed Web of Science ®Google Scholar
• Johnston DG, Prescott RV, Kendall-Taylor P et al. Hyperprolactinemia. Long-term effects of bromocriptine. Am. J. Med.75, 868–874 (1983).
   PubMed Web of Science ®Google Scholar
• Moriondo P, Travaglini P, Nissim M et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J. Clin. Endocrinol. Metab.60(25), 764–772 (1985)
   Google Scholar
• Cannavo S, Curto L, Squadrito S et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest.22(5), 354–359 (1999).
   Google Scholar
• Colao A, Di Sarno A, Landi ML et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab.85(6), 2247–2252 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Paracchi A, Mattei AM et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol.126(6), 489–494 (1992).
   PubMedGoogle Scholar
• Muratori M, Arosio M, Gambino G et al. Use of cabergoline in the long-treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest.20(9), 537–546 (1997).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Cappabianca P et al. Withdrawal of long-term cabergoline therapy for tumoural and nontumoural hyperprolactinemia. N. Engl. J. Med.349(21), 2023–2033 (2003).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Pivonello A et al. Dopamine receptor agonists for treating prolactinomas. Expert Opin. Investig. Drugs11(6), 787–800 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Abs R, Bevan JS. Treatment of macroprolactinoma with cabergoline: a staudy of 85 patients. Clin Endocrinol.46(4), 409–413 (1997).
   PubMed Web of Science ®Google Scholar
• Passos VQ, Souza JJ, Musolino NR. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab.87, 3578–3582 (2002).
   Google Scholar
• Turner HE, Adams CB, Wass JA. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative do dopamine agonists? Eur. J. Endocrinol.140, 43–47 (1999).
   PubMed Web of Science ®Google Scholar
• Losa M, Mortini P, Barzaghi R et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab.87(7), 3180–3186 (2002).
   PubMed Web of Science ®Google Scholar
• Soule SG, Farhi J, Conway GS et al. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin. Endocrinol.44(6), 711–716 (2003).
   Google Scholar
• Webster J, Page MD, Bevan JS et al. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function test. Clin. Endocrinol.36(1), 35–44 (1992).
   Google Scholar
• Feigenbaum SL, Downey DE, Wilson CB et al. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J. Clin. Endocrinol. Metab.81(5), 1711–1719 (1996).
   PubMed Web of Science ®Google Scholar
• Minniti G, Traish D, Ashley A et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J. Clin. Endocrinol. Metab.90(2), 800–804 (2005).
   PubMed Web of Science ®Google Scholar
• Becker G, Kocher M, Kortmann RD et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahl. Onkol.4, 173–186 (2002).
   Google Scholar
• Hayashi M, Izawa M, Hiyama H et al. Gamma knife radiosurgery for pituitary adenomas. Stereotact. Funct. Neurosurg.72(Suppl. 1), 111–118 (1999).
   Google Scholar
• Izawa M, Hayashi M, Nakaya K et al. gamma knife radiosurgery for pituitary adenomas. J. Neurosur.93(Suppl. 3), 19–22 (2000).
   Google Scholar
• Mokry M, Ramschak-Schwarzer S, Simbrunner J et al. A six year experience with the postoperative radiosurgical management of pituitary adenomas. Stereotact. Funct. Neurosurg.72(Suppl. 1), 88–100 (1999).
   Google Scholar
• Marek J, Ježková J, Hána V et al. gamma knife radiosurgery in the treatment of acromegaly and prolactinomas. (Abstract PO 0459, 13 Intern. Congress Endocrinol. Rio 2008). Endocrinol. Metab.52(Suppl. 6 Pt II), 952 (2008).
   Google Scholar
• Ježková J, Hána V, Kršek M et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin. Endocrinol. DOI: 10.1111/j.1365-2265.2008.03384.x (2009) (Epub ahead of print).
   Google Scholar
• Colao A, Bárcena DG, Chanson P et al. Pregnancy outcome following caberoline treatment: extended results from a 12 year observational study. Clin. Endocrinol.68(1), 66–71 (2008).
   PubMed Web of Science ®Google Scholar
• Ciccarelli E, Grottoli S, Razzore P et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest.20, 547–551 (1997).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi ML et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab.82(11), 3574–3579 (1997).
   PubMed Web of Science ®Google Scholar
• Colao A, Vitale G, Cappabianca P et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24 month treatment on prolactin levels, tumor mass, recovery of piruitary function, and semen analysis. J. Clin. Endocrinol. Metab.89(4), 1704–1711 (2004).
   PubMed Web of Science ®Google Scholar
• Wang C, Lam KS, Ma JT et al. Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol.27, 363–371 (1987).
   Google Scholar
• Di Sarno A, Landi ML, Marzullo P et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin. Endocrinol.53, 53–60 (2000).
   PubMed Web of Science ®Google Scholar
• Biswas M, Smith J, Jadon D et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin. Endocrinol.63(1), 26–31 (2005).
   Google Scholar